News Roivant wins FDA approval for first targeted dermatomyositis... Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
News Almirall and IRB Barcelona team up to tackle skin disease Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs.
Events Partner Content 3rd Annual Dermatology Drug Development Summit Industry meeting on advancing derm drug development
News Roivant wins FDA approval for first targeted dermatomyositis... Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.